Merck advances plan to shed consumer biz

Share this article:

The Wall Street Journal reported today that Merck will begin meeting with potential buyers of its consumer business next week and, citing unnamed sources, wrote that the price tag could be over $10 billion. Merck inherited its consumer business from Schering-Plough, which it acquired in 2009. In an investor note Wednesday night, ISI Group analyst Mark Schoenebaum stated that the final bid will likely be due in late March. Merck consumer products include Coppertone sunscreen, and Claritin allergy medication, among others.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.